Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes

(2012) Iskandar Idris et al.   ARCHIVES OF INTERNAL MEDICINE

The effect of metformin and thiazolidinedione use on lung cancer in diabetics

(2012) Peter J Mazzone et al.   BMC CANCER

Pioglitazone and bladder cancer: a propensity score matched cohort study

(2012) Li Wei et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

(2012) I. N. Colmers et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Impact of Hypoglycemia Associated With Antihyperglycemic Medications on Vascular Risks in Veterans With Type 2 Diabetes

(2012) Y. Zhao et al.   DIABETES CARE

Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes: A nationwide, population-based, case-control study

(2012) S.-W. Chen et al.   DIABETES CARE

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis

(2012) Zhaowei Zhu et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

(2012) A. Neumann et al.   DIABETOLOGIA

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

(2012) R. J. Stevens et al.   DIABETOLOGIA

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs

(2012) H. M. Colhoun et al.   DIABETOLOGIA

Thiazolidinedione safety

(2012) Jacqueline Kung et al.   Expert Opinion On Drug Safety

What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes

(2012) Christopher Ll. Morgan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A new “Comparative Effectiveness” assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone

(2012) Richard Tannen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

(2012) L. Azoulay et al.   BMJ-British Medical Journal

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study

(2011) J. D. Lewis et al.   DIABETES CARE

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

(2011) D. Russell-Jones et al.   DIABETES CARE

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus

(2011) Chia-Hsuin Chang et al.   HEPATOLOGY

Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: An analysis of the PROactive study population

(2011) Wolfram Doehner et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients

(2011) Mei-Yueh Lee et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

(2011) Ralph A. DeFronzo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?

(2010) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

(2010) D. J. Betteridge   DIABETIC MEDICINE

Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus

(2010) Giuseppe Derosa   DRUGS

Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone

(2010) David J. Graham et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Severe Hypoglycemia and Risks of Vascular Events and Death

(2010) Sophia Zoungas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glitazone Use Associated with Diabetic Macular Edema

(2009) Donald S. Fong et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

(2009) John Dormandy et al.   DRUG SAFETY

Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors

(2009) G. Schernthaner   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

(2009) Steven M. Brunelli et al.   KIDNEY INTERNATIONAL

Impact of peripheral arterial disease in patients with diabetes—Results from PROactive (PROactive 11)

(2008) J.A. Dormandy et al.   ATHEROSCLEROSIS

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

(2008) Y. K. Loke et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Monitoring the Safety of Pioglitazone

(2008) Rachna Kasliwal et al.   DRUG SAFETY

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease

(2007) C. A. Schneider et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY